BNGO Relative Valuation
BNGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNGO is overvalued; if below, it's undervalued.
Historical Valuation
Bionano Genomics Inc (BNGO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.78. The fair price of Bionano Genomics Inc (BNGO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.70
Fair
-0.50
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Bionano Genomics Inc. (BNGO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -6.47. The thresholds are as follows: Strongly Undervalued below -29.79, Undervalued between -29.79 and -18.13, Fairly Valued between 5.20 and -18.13, Overvalued between 5.20 and 16.86, and Strongly Overvalued above 16.86. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.49
EV/EBIT
Bionano Genomics Inc. (BNGO) has a current EV/EBIT of -0.49. The 5-year average EV/EBIT is -6.31. The thresholds are as follows: Strongly Undervalued below -28.22, Undervalued between -28.22 and -17.27, Fairly Valued between 4.64 and -17.27, Overvalued between 4.64 and 15.59, and Strongly Overvalued above 15.59. The current Forward EV/EBIT of -0.49 falls within the Historic Trend Line -Fairly Valued range.
0.50
PS
Bionano Genomics Inc. (BNGO) has a current PS of 0.50. The 5-year average PS is 23.21. The thresholds are as follows: Strongly Undervalued below -53.84, Undervalued between -53.84 and -15.31, Fairly Valued between 61.73 and -15.31, Overvalued between 61.73 and 100.25, and Strongly Overvalued above 100.25. The current Forward PS of 0.50 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Bionano Genomics Inc. (BNGO) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.80. The thresholds are as follows: Strongly Undervalued below -6.17, Undervalued between -6.17 and -3.98, Fairly Valued between 0.39 and -3.98, Overvalued between 0.39 and 2.57, and Strongly Overvalued above 2.57. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Bionano Genomics Inc. (BNGO) has a current P/FCF of 0.00. The 5-year average P/FCF is 22.40. The thresholds are as follows: Strongly Undervalued below -174.69, Undervalued between -174.69 and -76.15, Fairly Valued between 120.94 and -76.15, Overvalued between 120.94 and 219.48, and Strongly Overvalued above 219.48. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Bionano Genomics Inc (BNGO) has a current Price-to-Book (P/B) ratio of 0.33. Compared to its 3-year average P/B ratio of 0.66 , the current P/B ratio is approximately -49.47% higher. Relative to its 5-year average P/B ratio of 4.02, the current P/B ratio is about -91.74% higher. Bionano Genomics Inc (BNGO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -263.60%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -161.66% , the current FCF yield is about -100.00% lower.
0.33
P/B
Median3y
0.66
Median5y
4.02
-106.08
FCF Yield
Median3y
-263.60
Median5y
-161.66
Competitors Valuation Multiple
The average P/S ratio for BNGO's competitors is 0.00, providing a benchmark for relative valuation. Bionano Genomics Inc Corp (BNGO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 21.31%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BNGO decreased by 90.18% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.07M to 7.37M.
The secondary factor is the P/E Change, contributed -27.33%to the performance.
Overall, the performance of BNGO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Bionano Genomics Inc (BNGO) currently overvalued or undervalued?
What is Bionano Genomics Inc (BNGO) fair value?
How does BNGO's valuation metrics compare to the industry average?
What is the current P/B ratio for Bionano Genomics Inc (BNGO) as of Dec 05 2025?
What is the current FCF Yield for Bionano Genomics Inc (BNGO) as of Dec 05 2025?
What is the current Forward P/E ratio for Bionano Genomics Inc (BNGO) as of Dec 05 2025?